Trials / Completed
CompletedNCT00785954
Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]
Inhibition of Delta-protein Kinase C for the Reduction of Infarct Size in Acute Myocardial Infarction
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,180 (actual)
- Sponsor
- KAI Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether KAI-9803 is safe and effective in reducing infarct size in subjects with ST elevation myocardial infarction (heart attack) undergoing a percutaneous coronary intervention (PCI). A select number of sites will also participate in a substudy where eligible patients will undergo an additional procedure;cardiac magnetic resonance imaging.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KAI-9803 | STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2010-07-01
- Completion
- 2011-05-01
- First posted
- 2008-11-05
- Last updated
- 2011-09-02
Locations
126 sites across 18 countries: United States, Australia, Belgium, Canada, Czechia, Denmark, Finland, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden
Source: ClinicalTrials.gov record NCT00785954. Inclusion in this directory is not an endorsement.